A Phase 1, Dose-Escalation, Positron Emission Tomography Study to Assess the Safety, Pharmacokinetics, Dosimetry and Biodistribution of GEH200521 (18F) Injection Co-Administered With GEH200520 Injection in Healthy Volunteers
← catalyst calendarSponsored by GE Healthcare (industry) · GEHC — their whole pipeline →. With PPD Development, LP, Fortrea.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Diagnostic
Enrollment
22actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-02 | actual | When the study began enrolling |
| Primary completion | 2026-02-19 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-23 | actual | The whole study's end, after follow-up |
| First posted | 2024-05-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Interventions
- Drug: GEH200520 Injection and GEH200521 (18F) Injection
- Diagnostic test: Static - PET/CT scan
Primary outcome
what the primary-completion date above is the date OFIncidence of all TEAEs
measured 7 days
Permalink · GEHC's whole pipeline · Catalyst calendar · Every registered study · What changed